CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under ...

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

Bristol Myers Squibb buys 2seventy bio for $286 million, strengthening its cancer portfolio with Abecma CAR-T therapy for ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Bristol Myers Squibb is acquiring 2seventy bio ... Graybosch noted that 2seventy CEO Chip Baird stated at an investor conference last week that his company’s move toward profitability makes ...

Frederic N. Schwartz became president and CEO of Bristol-Myers when Henry Bristol chose to give up some of his responsibilities as he approached the age of 70. "In 1955, Squibb received one of the ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb ... said Chip Baird, chief executive officer, 2seventy bio.

Further information is available at www.AbecmaREMS.com or contact Bristol-Myers Squibb at 1-866-340-7332. Hypersensitivity Reactions: Allergic reactions may occur with the infusion of ABECMA.